GlobeNewswire: China Nuokang Bio-Pharmaceutical Inc. Contains the last 10 of 54 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:14:04ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2013/02/07/521682/10021020/en/China-Nuokang-Bio-Pharmaceutical-Inc-Announces-Completion-of-Merger.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Announces Completion of Merger2013-02-07T09:54:57Z<![CDATA[BEIJING, Feb. 7, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced the completion of the merger (the "Merger") with Kingbird Mergerco. Inc. ("Merger Sub"), a wholly-owned subsidiary of Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company, pursuant to the agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Parent and Merger Sub, and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited. As a result of the merger, the Company became a direct wholly-owned subsidiary of Parent.]]>https://www.globenewswire.com/news-release/2013/01/29/519201/10019691/en/China-Nuokang-Bio-Pharmaceutical-Inc-to-Reconvene-Adjourned-Extraordinary-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary General Meeting of Shareholders2013-01-29T14:00:00Z<![CDATA[BEIJING, Jan. 29, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it will reconvene the extraordinary general meeting of shareholders (the "EGM") that was previously adjourned on January 15, 2013. The EGM will be reconvened at 9:30 a.m. (Beijing time) on February 6, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreement (the "Plan of Merger") and the transactions contemplated thereby (including the proposed merger). ]]>https://www.globenewswire.com/news-release/2013/01/15/516410/10018146/en/China-Nuokang-Bio-Pharmaceutical-Inc-Adjourns-Extraordinary-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Adjourns Extraordinary General Meeting of Shareholders2013-01-15T09:00:00Z<![CDATA[BEIJING, Jan. 15, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it has adjourned its extraordinary general meeting of shareholders that was called to authorize and approve the proposed merger with an affiliate of Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company, pursuant to the agreement and plan of merger dated as of September 27, 2012, among the Company, Parent and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited. Parent has advised the Company that it requires additional time to obtain its contemplated debt financing for the pending transaction. Apart from the motion to adjourn, no other business was conducted at the extraordinary general meeting of shareholders on January 15, 2013. The resolutions set out in the notice of the extraordinary general meeting dated December 17, 2012 will be considered and voted on at such time as the adjourned extraordinary general meeting is resumed. The Company intends to resume the adjourned extraordinary general meeting of shareholders as soon as practicable following confirmation from Parent that the debt financing will be available at the closing of the transaction, and Parent has further advised the Company that it expects this will not be later than March 21, 2013. The Company will give notice to shareholders of the date on which the adjourned extraordinary general meeting will be resumed as soon as a date is selected, and in any event not less than seven calendar days prior to such resumed meeting.]]>https://www.globenewswire.com/news-release/2013/01/14/516237/10018003/en/China-Nuokang-Bio-Pharmaceutical-Inc-Proposes-to-Adjourn-Extraordinary-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Proposes to Adjourn Extraordinary General Meeting of Shareholders2013-01-14T14:00:00Z<![CDATA[BEIJING, Jan. 14, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it intends to adjourn its extraordinary general meeting of shareholders to be held on January 15, 2013 at 9:30 a.m. (Beijing time) at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong that was called to authorize and approve the proposed merger with an affiliate of Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company, pursuant to the agreement and plan of merger dated as of September 27, 2012, among the Company, Parent and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited. The Company intends to hold the extraordinary general meeting of shareholders on January 15, 2013, but immediately adjourn the meeting without conducting any business. No vote will be taken on January 15, 2013 for any resolution set forth in the notice of the extraordinary general meeting dated December 17, 2012.]]>https://www.globenewswire.com/news-release/2012/12/14/511689/10015738/en/China-Nuokang-Bio-Pharmaceutical-Inc-Announces-Extraordinary-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Announces Extraordinary General Meeting of Shareholders2012-12-14T14:00:00Z<![CDATA[BEIJING, Dec. 14, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at 9:30 a.m. (Beijing time) on January 15, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreement (the "Plan of Merger") and the transactions contemplated thereby (including the merger).]]>https://www.globenewswire.com/news-release/2012/11/25/507156/10013461/en/China-Nuokang-Bio-Pharmaceutical-Inc-Reports-Third-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Reports Third Quarter 2012 Financial Results2012-11-25T14:00:00Z<![CDATA[3Q12 Revenue was RMB75.4 Million ($12.0 Million)]]>https://www.globenewswire.com/news-release/2012/11/05/502344/10011068/en/China-Nuokang-Bio-Pharmaceutical-Inc-to-Report-Third-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. to Report Third Quarter 2012 Financial Results2012-11-05T13:00:00Z<![CDATA[BEIJING, Nov. 5, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release third quarter 2012 financial results on Sunday, November 25, 2012 .]]>https://www.globenewswire.com/news-release/2012/09/27/493319/10006478/en/China-Nuokang-Bio-Pharmaceutical-Inc-Enters-Into-Definitive-Agreement-for-Going-Private-Transaction.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Enters Into Definitive Agreement for Going Private Transaction2012-09-27T13:00:00Z<![CDATA[BEIJING, Sept. 27, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that it has entered into an Agreement and Plan of Merger (the "Merger Agreement") with Kingbird Investment Inc. ("Parent"), a Cayman Islands exempted company with limited liability and beneficially owned by Ms. Yuhuan Zhu, the wife of Mr. Baizhong Xue, the Company's Chairman and Chief Executive Officer, and Kingbird Mergerco. Inc., a Cayman Islands exempted company with limited liability and a direct wholly-owned subsidiary of Parent ("Merger Sub").]]>https://www.globenewswire.com/news-release/2012/08/22/483521/10002748/en/China-Nuokang-Bio-Pharmaceutical-Inc-Reports-Second-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. Reports Second Quarter 2012 Financial Results2012-08-22T20:01:00Z<![CDATA[2Q12 Revenue was RMB72.9 Million ($11.5 Million)]]>https://www.globenewswire.com/news-release/2012/08/01/275212/10000441/en/China-Nuokang-Bio-Pharmaceutical-Inc-to-Report-Second-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=10652China Nuokang Bio-Pharmaceutical Inc. to Report Second Quarter 2012 Financial Results2012-08-01T12:00:00Z<![CDATA[BEIJING, Aug. 1, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release second quarter 2012 financial results on Wednesday, August 22, 2012 after the market closes.]]>